English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/72697
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies

AuthorsFerrer, B.; Gorriti, M. A.; Palomino, A.; Gornemann, I.; Diego, Y. de; Bermúdez-Silva, Francisco Javier; Bilbao, Ainhoa; Fernández-Espejo, E.; Moratalla, Rosario ; Navarro, Miguel; Rodríguez de Fonseca, Fernando
Issue Date2007
CitationEuropean Journal of Pharmacology 559: 180-183 (2007)
AbstractThe contribution of the endocannabinoid system to dopamine-mediated disorganized behavior in schizophrenia is discussed. We used a model of concurrent stimulation of dopamine D1 and D2 receptors to evaluate the role of this system in dopamine-mediated stereotypies measured in a hole-board test. Pretreatment with the cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1 mg/kg) potentiated stereotyped behavior induced by coadministration of the dopamine D1 receptor agonist SKF 38393 (0.05, 0.1 and 1 mg/kg) and the dopamine D2 receptor agonist quinpirole (0.25 mg/kg). Thus, the endocannabinoid system acts as a brake for abnormal behavior associated with dopaminergic overactivation. © 2007 Elsevier B.V. All rights reserved.
Identifiersdoi: 10.1016/j.ejphar.2007.01.009
issn: 0014-2999
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.